Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04139941
Other study ID # 8162-2/2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 31, 2019
Est. completion date March 31, 2020

Study information

Verified date July 2020
Source Foundation for Innovative New Diagnostics, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study evaluates the sensitivity and specificity performance of three Hepatitis C Virus (HCV) rapid diagnostic tests (RDTs) in freshly collected fingerstick whole blood, as well as serum and plasma (Premier Medical Corporation First Response HCV RDT; Beijing Wantai HCV RDT; AccessBio Care Start HCV under development). Performance is compared to the SD Bioline HCV RDT, as well as a composite reference standard, consisting of two enzyme Immunoassay and a line immunoassay.


Description:

Hepatitis C virus (HCV) infection is a major public health burden, with an estimated 71 million patients being infected globally. If undiagnosed, HCV infection can lead to severe liver damage, including hepatocellular carcinoma (HCC). The World Health Organization (WHO) recently set a target to eliminate HCV by 2030. The first critical step in reaching this target is to accurately identify people infected with HCV. Globally, significant gaps remain in diagnosis of HCV, with four out of five people infected still unaware of their status, largely due to lack of access to testing services.

In resource-limited settings (RLS), laboratory-based testing remains a mainstay for HCV screening and confirmatory testing. Such laboratory-based assays rely on transportation of temperature-sensitive samples from clinic sites to centralized laboratories, high-tech equipment and highly skilled laboratory technicians, limiting the scope of access to testing and resulting in long turn-around times for results. In recent years, new technologies have been developed to decentralize HCV screening and confirmatory testing using point-of-care (POC) assays to overcome these barriers and improve patient outcomes.

Rapid diagnostic tests (RDT) for screening for HCV are affordable, accurate, easy to use by healthcare workers, and robust in field settings. Although a number of HCV RDTs are on the market, currently only two have received WHO pre-qualification (PQ) status, demonstrating their accuracy and reliability for use in the field in RLS. Data on a number of other RDTs indicate their suitability for use. More data is needed, however, in field settings for these HCV RDTs, to demonstrate their accuracy and quality in end-user studies and to provide evidence for WHO PQ approval.

Based on the results of a recent FIND laboratory evaluation assessing the performance of 13 HCV RDTs using archived plasma samples, we have selected three candidate HCV RDTs ("study RDTs") for further evaluation in field settings (e.g. primary healthcare facilities). The performance of these RDTs measured in frozen plasma specimens indicated that they have a high potential to meet WHO PQ performance criteria in freshly collected samples. In addition, the manufacturers each demonstrate evidence of engagement to pursue both CE-mark status and the WHO PQ process, showing commitment to delivering quality-assured tests to the market.

The data generated during this study will be used to inform national and international stakeholders on HCV RDT performance in field settings and shared with manufacturers to support the evidence package for WHO PQ and/or CE-marking.


Recruitment information / eligibility

Status Completed
Enrollment 1540
Est. completion date March 31, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- = 18 years of age

- Known or unknown HCV serology

- No history of past or present HCV treatment

- Willing to undergo the information and consenting procedure and subsequently have enough time to participate in the study

- Willing to provide 13 ml venepuncture blood sample and a minimum of four whole blood fingerstick samples

- Willing to perform an HIV test

- Individuals can already be registered at the local site or register for the first time when enrolling in the study

Exclusion Criteria:

- Participants not able to consent themselves (incapable)

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Test for HCV antibodies with an RDT
Fingerstick whole blood, plasma and serum of each participant is tested with three investigational HCV RDTs and one reference HCV RDT. Plasma is also used for testing with the composite reference standard, HCV viral load and genotyping. All participants are also tested for HIV with an HIV RDT.

Locations

Country Name City State
Cambodia Sihanouk Hospital Centre of Hope Phnom Penh
Georgia National Center for Disease Control & Public Health/Lugar Center Tbilisi

Sponsors (2)

Lead Sponsor Collaborator
Foundation for Innovative New Diagnostics, Switzerland Institute of Tropical Medicine, Belgium

Countries where clinical trial is conducted

Cambodia,  Georgia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity and specificity of HCV RDTs compared to a composite reference standard 1.1 Point estimates of sensitivity, specificity, positive and negative predicative values (with 95% confidence intervals) and Cohen's Kappa Coefficient (?) of inter-rater agreement for each RDT, using a combination of two EIAs (Enzyme Immunoassay) and an LIA (Line immunoassay) as a composite reference standard for the detection of anti-HCV antibodies in fingerstick whole blood, EDTA plasma and serum. through study completion, on average 1 year
Secondary Sensitivity and specificity of HCV RDTs compared to an HCV RDT pre-qualified by WHO as reference standard 2.1 Point estimates of sensitivity, specificity, positive and negative predicative values (with 95% confidence intervals) and Cohen's Kappa Coefficient (?) of inter-rater agreement for each RDT, using the WHO-PQ RDT as reference standard for the detection of anti-HCV antibodies in fingerstick whole blood, EDTA plasma and serum through study completion, on average 1 year
Secondary Operational characteristics 2.2 Operational characteristics and usability of study RDTs:
- Rate of invalid test results /errors: Percentage of invalid test results/errors by RDT, site and error type
through study completion, on average 1 year
Secondary Operational characteristics Operational characteristics and usability of study RDTs:
- Technical appraisal rating on kit instructions, labelling and test conduct, on a Likert scale
through study completion, on average 1 year
See also
  Status Clinical Trial Phase
Completed NCT02487030 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection Phase 3
Active, not recruiting NCT05460130 - Implementing HCV Treatment for High-risk Populations in Austin, Texas N/A
Completed NCT02220998 - Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection Phase 3
Terminated NCT01052090 - Safety and Efficacy Study in Hepatitis C Patients With PHN121 Phase 1/Phase 2
Completed NCT02537379 - Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection N/A
Recruiting NCT04156945 - Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men N/A
Terminated NCT02510300 - A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
Withdrawn NCT04309734 - Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects Phase 1/Phase 2
Active, not recruiting NCT04001608 - Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients Phase 3
Completed NCT04112303 - Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis Phase 3
Completed NCT02251717 - Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection Phase 2
Recruiting NCT05092074 - Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
Recruiting NCT04005248 - Prevalence of HCV in HIV-negative MSM N/A
Completed NCT02249182 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection Phase 2
Completed NCT02939989 - Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study Phase 3
Completed NCT01718145 - A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects Phase 3
Completed NCT01482611 - A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382 Phase 1
Completed NCT00255177 - Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients Phase 2
Terminated NCT02600351 - Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies Phase 3
Completed NCT04980157 - CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers